In the News
Announcement / April 2024
New Published Data in 422 patients establishes the safety of StitchKit in Robotic Sacrocolpopexy.
The use of StitchKit reduced reliance on robotically trained/skilled bedside assistants, eliminated a port, gave surgeons full autonomy of suture/needle management, and ensured that all needles were accounted for.
Announcement / December 2023
StitchKit highlighted as a new novel device in pelvic organ prolapse by Contemporary OB/GYN.
Beyond simply eliminating the issue of lost needles, use of StitchKit provides efficiencies that can result in significantly shorter operative times.
Press Release / February 2023
Origami Surgical Inc. announces FDA clearance for a label expansion for the insertion and removal of our StitchKit® device through an existing 8mm trocar site incision under direct endoscopic visualization.
Madison, NJ, February 21, 2023 – Origami Surgical has received a new FDA clearance for the insertion and removal of our StitchKit® device.
Announcement / December 2022
Origami announces our latest clinical white paper, which compares operative times for a robotic-assisted suture intensive procedure.
Two surgeons performed the same procedure, one surgeon utilized the StitchKit® and the other with traditional suturing. The outcome is a time savings of ~30 minutes per case when using StitchKit®.
Announcement / August 2021
Origami Surgical is pleased to announce the FDA clearance for four new suture materials to our StitchKit® technology platform.
These new materials give the surgeon additional flexibility when selecting their suture preference when utilizing StitchKit®.
Press Release / March 2021
Origami Surgical Inc. announces FDA clearance for its next generation StitchKit® robotic platform technology with three new products.
Origami Surgical announces the clearance of their newest technology platform which will provide surgeons with additional StitchKit® devices tailored to meet their specific robotic-assisted suturing needs.
Press Release / October 2020
Origami Surgical Inc. announces FDA clearance of its newest device, StitchKit®PARK™
Madison, NJ, October 9, 2020 – Origami Surgical announced that the FDA has cleared StitchKit PARK, a device that enables surgeons to customize the contents of its StitchKit suture-delivery device with the sutures of their choice.
Media
For media inquiries, please email us at info@stitchkit.com.
